A detailed history of Lindbrook Capital, LLC transactions in Pacira Bio Sciences, Inc. stock. As of the latest transaction made, Lindbrook Capital, LLC holds 118 shares of PCRX stock, worth $2,331. This represents 0.0% of its overall portfolio holdings.

Number of Shares
118
Previous 174 32.18%
Holding current value
$2,331
Previous $4,000 75.0%
% of portfolio
0.0%
Previous 0.0%

Shares

7 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 01, 2024

SELL
$11.7 - $28.46 $655 - $1,593
-56 Reduced 32.18%
118 $1,000
Q2 2024

Jul 31, 2024

BUY
$25.5 - $31.51 $765 - $945
30 Added 20.83%
174 $4,000
Q4 2023

Jan 31, 2024

BUY
$26.32 - $34.31 $3,263 - $4,254
124 Added 620.0%
144 $4,000
Q3 2023

Oct 25, 2023

BUY
$30.68 - $40.09 $613 - $801
20 New
20 $0
Q1 2023

Apr 26, 2023

BUY
$35.53 - $43.38 $2,700 - $3,296
76 New
76 $3,000
Q3 2022

Nov 10, 2022

BUY
$51.24 - $58.89 $358 - $412
7 Added 87.5%
15 $1,000
Q2 2022

Aug 01, 2022

BUY
$51.49 - $81.64 $411 - $653
8 New
8 $0

Others Institutions Holding PCRX

About Pacira BioSciences, Inc.


  • Ticker PCRX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 45,824,200
  • Market Cap $905M
  • Description
  • Pacira BioSciences, Inc. provides non-opioid pain management and regenerative health solutions for healthcare practitioners and their patients in the United States. The company offers EXPAREL, a bupivacaine liposome injectable suspension; ZILRETTA, a triamcinolone acetonide extended-release injectable suspension; and iovera system, a non-opioid ...
More about PCRX
Track This Portfolio

Track Lindbrook Capital, LLC Portfolio

Follow Lindbrook Capital, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Lindbrook Capital, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Lindbrook Capital, LLC with notifications on news.